<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals Ltd has submitted its Initial Disclosure under SEBI's Large Corporate framework, which requires certain large listed entities to disclose their borrowings and steps taken for raising incremental borrowings through the issuance of debt securities. The actual details table from the BSE filing was not accessible due to a broken link on the BSE website, so specific numbers such as outstanding borrowings, credit rating, or incremental borrowing target are not available from the provided document.
This is a routine regulatory compliance filing under SEBI's Large Corporate norms and does not, by itself, indicate any positive or negative business development. Investors looking for actionable details should refer to the company's latest annual report or contact the company directly for the full disclosure contents.